Trial Profile
A Study Investigating the Efficacy of Icotinib in Advanced Non-Small-Cell Lung Cancer Patients with Uncommon EGFR exon 20 Insert Mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2017
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.